Roswell Park Comprehensive Cancer Center researchers have made another step toward personalizing cancer treatment while reducing the toxicity of certain cancer drugs using simple, noninvasive blood tests.
In December 2016, the Parker Institute for Cancer Immunotherapy and the Cancer Research Institute (CRI) announced a major collaboration focused on an emerging area of cancer research: neoantigens. These small proteins on the surface of cancer cells arise from mutations often unique to a tumor, making personalized immunotherapies like cancer vaccines a possibility.
Sharon McCann never smoked. Neither did her parents or her husband. She did not have any of the risk factors for lung cancer. “It just happened,” she says.